Key facts
- This page summarizes Thomas Cusack's Form 4 filing for HERON THERAPEUTICS, INC. /DE/ (HRTX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 12 Nov 2025, 09:20.
Thomas Cusack - 08 Nov 2025 Form 4 Insider Report for HERON THERAPEUTICS, INC. /DE/ (HRTX)
- Reporting relationship
- Director
- Issuer ticker
- HRTX
- Reported as of
- 08 Nov 2025
- Net transaction value
- +$249,999
- SEC form
- 4
- Accepted by SEC
- 12 Nov 2025, 09:20:31 UTC
- Prior SEC filing
- 07 Nov 2025
- Next SEC filing
- 03 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kathryn Lester Attorney-in-fact for Thomas P. Cusack
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Thomas Cusack filed Form 4 for HERON THERAPEUTICS, INC. /DE/ (HRTX) on 12 Nov 2025.
Change
- Previous filing in this sequence was filed on 07 Nov 2025.
- Current net transaction value: +$249,999.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002094824
Primary reporting owner
Cusack Thomas
- Relationship
- Director
- Address
- 100 REGENCY FOREST DRIVE, SUITE 300, CARY
- Signature
- /s/ Kathryn Lester Attorney-in-fact for Thomas P. Cusack
- Signature date
- 12 Nov 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HRTX
transaction
Common Stock
Award
- Transaction value
- Shares
- +37,879
- Change %
- Price
- Shares after
- 37,879
- Date
- 08 Nov 2025
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
HRTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $249,999
- Shares
- +227,272
- Change %
- Price
- $1.10
- Shares after
- 227,272
- Date
- 08 Nov 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 227,272
- Exercise price
- $1.10
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The shares were granted as restricted stock units which vest in 16 equal quarterly installments beginning one quarter after the date of grant.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of common stock.
Footnote F3
The stock options vest and become exercisable in 48 equal monthly installments beginning one month after the date of grant.